Re-statement of Directors' Interests
e-Therapeutics plc ("e-Therapeutics" or the "Company")
Re-statement of Directors' Interests
Following the successful completion of the Placings announced on 15 March 2011, the interests of the Directors of the Company are as follows:
|
Director |
Title |
Number |
Percentage |
|
Prof. Malcolm Young (1) |
Chief Executive Officer |
20,620,482 |
15.03% |
|
Johnny Cordiner (1) |
Finance Director |
362,060 |
0.30% |
|
Novotech (1) |
(n/a - see footnote) |
1,640,236 |
1.20% |
|
Stephen Self |
Development Director |
86,413 |
0.06% |
|
Prof. Oliver James |
Non-executive Chairman |
38,500 |
0.03% |
|
Brad Hoy |
Non-executive Director |
0 |
0.00% |
(1) The Novotech holding in the Company comprises holdings by Novotech Investment
Limited ("NIL") and Novotech Syndicate LLP ("NSL"). Malcolm Young and John Cordiner are each directors and shareholders of NIL and equity partners in NSL.
Through their interests in the Novotech entities, each of Malcolm Young and John Cordiner indirectly holds a further 428,512 shares in e-Therapeutics, representing 0.3% of the total issued share capital.
For more information, please contact:
e-Therapeutics plc
Malcolm Young / John Cordiner
Tel: +44 (0) 191 233 1317
E-mail: info@etherapeutics.co.uk
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Andrew Burnett / Aubrey Powell
Tel: +44 (0) 20 7459 3600
www.panmure.com
This information is provided by RNS